Literature DB >> 11888547

The medical benefit of 5-HT research.

Brian J Jones1, Thomas P Blackburn.   

Abstract

5-HT research is now more than 50 years old, and it has generated a wealth of therapeutic agents, some of which have had a major impact on disease management. The 5-HT reuptake inhibitors (SSRIs) are among the most widely prescribed drugs for treating depression and a variety of other disorders including anxiety, social phobia and premenstrual dysphoria (PMD). The other major success stories of 5-HT research are the discovery of 5-HT1B/D receptor agonists for treating migraine and 5-HT3 receptor antagonists for chemotherapy and radiation-induced emesis. The role of 5-HT in the mechanism of action of antipsychotic agents remains a topic of intense research, which promises better treatments for schizophrenia in the future. Compounds interacting with 5-HT1F, 5-HT2C, 5-HT6 and 5-HT7 receptors are currently under investigation and may prove to have important therapeutic applications in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888547     DOI: 10.1016/s0091-3057(01)00745-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  43 in total

1.  Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E.

Authors:  Johannes Kapeller; Dorothee Möller; Felix Lasitschka; Frank Autschbach; Ruud Hovius; Gudrun Rappold; Michael Brüss; Michael D Gershon; Beate Niesler
Journal:  J Comp Neurol       Date:  2011-02-15       Impact factor: 3.215

2.  Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.

Authors:  Małgorzata Jarończyk; Karol Wołosewicz; Mari Gabrielsen; Gabriel Nowak; Irina Kufareva; Aleksander P Mazurek; Aina W Ravna; Ruben Abagyan; Andrzej J Bojarski; Ingebrigt Sylte; Zdzisław Chilmonczyk
Journal:  Eur J Med Chem       Date:  2012-01-15       Impact factor: 6.514

3.  Modulation of 5-HT7 receptor: effect on object recognition performances in mice.

Authors:  Thomas Freret; Eleni Paizanis; Gregory Beaudet; Andreia Gusmao-Montaigne; Gerald Nee; François Dauphin; Valentine Bouet; Michel Boulouard
Journal:  Psychopharmacology (Berl)       Date:  2013-08-31       Impact factor: 4.530

4.  5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!

Authors:  N M Barnes
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Chronic administration of citalopram in olfactory bulbectomy rats restores brain 5-HT synthesis rates: an autoradiographic study.

Authors:  Shu Hasegawa; Arata Watanabe; Khanh Q Nguyen; Guy Debonnel; Mirko Diksic
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

6.  Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment.

Authors:  Katharine Herrick-Davis; Ellinor Grinde; Barbara A Weaver
Journal:  Eur J Pharmacol       Date:  2007-05-04       Impact factor: 4.432

7.  Serotonin modulates the population activity profile of olfactory bulb external tufted cells.

Authors:  Shaolin Liu; Jason L Aungst; Adam C Puche; Michael T Shipley
Journal:  J Neurophysiol       Date:  2011-10-19       Impact factor: 2.714

8.  Electrical interfacing of neurotransmitter receptor and field effect transistor.

Authors:  I Peitz; P Fromherza
Journal:  Eur Phys J E Soft Matter       Date:  2009-10       Impact factor: 1.890

9.  YKP1447, A Novel Potential Atypical Antipsychotic Agent.

Authors:  Seon Min Dong; Yong Gil Kim; Joon Heo; Mi Kyung Ji; Jeong Woo Cho; Byong Sung Kwak
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

Review 10.  A pharmacological analysis of mice with a targeted disruption of the serotonin transporter.

Authors:  Meredith A Fox; Anne M Andrews; Jens R Wendland; Klaus-Peter Lesch; Andrew Holmes; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2007-08-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.